rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PEPG
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Tuesday’s insider buys and sells: RA Capital invests $43M in PepGen By Investing.com
      14h agoInvesting.comPEPG
      RA Capital Management, PepGen director, buys $43.1 million in stock
      Nov 17Investing.comPEPG
      PepGen Inc. (PEPG) Discusses FREEDOM2 Lowest Dose Cohort Safety, Splicing and vHOT Results - Slideshow

      2026-11-13. The following slide deck was published by PepGen Inc.

      Nov 13Seeking AlphaPEPG
      PepGen (PEPG) Stock Sees Fair Value Lift After Encouraging EDODM1 Analyst Reactions
      Nov 13Yahoo FinancePEPG
      PepGen: Upgrade To 'Buy' On PGN-EDODM1 Splicing Data Comeback And 2027 Milestones

      PepGen is rated a Buy, after phase 2 DM1 data show 46.5% mean splicing correction, supporting a potential FDA meeting in 2H 2027.

      Nov 12Seeking AlphaPEPG
      PepGen Announces Pricing of $125 Million Public Offering
      Nov 12Yahoo FinancePEPG
      PepGen: Stock Soars On DM1 Data, But Caution Warranted On Small Sample Sizes (NASDAQ:PEPG)
      Nov 11Seeking AlphaPEPG
      PepGen’s stock skyrockets on record-breaking DM1 trial data
      Nov 11Yahoo FinancePEPG
      PepGen launches $125 million public stock offering
      Nov 10Investing.comPEPG
      PepGen soars on promising early data for muscular dystrophy drug
      Nov 10Yahoo FinancePEPG
      PepGen Stock Spikes 132% on Rare-Disease Win. These Rivals Are Feeling The Pressure.

      PepGen reports solid trial data for its rare-disease candidate, pressuring rivals developing competing therapies for myotonic dystrophy type 1.

      Nov 10Barron'sPEPG
      PepGen Stock Doubles in One Session - Here's Why
      Nov 10BenzingaPEPG
      12 Health Care Stocks Moving In Tuesday's Intraday Session
      Nov 10BenzingaPEPG
      PepGen Reports Phase 2 Myotonic Dystrophy Trial Results and $104.8 Million Cash Position
      Nov 10Yahoo FinancePEPG
      PepGen stock soars over 100% on positive Phase 2 trial data for DM1 drug
      Nov 10Investing.comPEPG
      PepGen reports splicing correction results in DM1 trial
      Nov 10Investing.comPEPG
      Why is PepGen stock surging today?
      Nov 10Investing.comPEPG
      PepGen updates trial data for muscle disorder therapy (PEPG)

      PepGen (PEPG) stock jumps as the company updates mid-stage trial for its lead asset, PGN-EDODM1, in myotonic dystrophy type 1, a rare genetic condition. Read more here.

      Nov 10Seeking AlphaPEPG
      PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
      Nov 10Yahoo FinancePEPG
      PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures
      Nov 10Yahoo FinancePEPG
      PepGen: Maintaining 'Hold,' PGN-EDODM1 Data Is A Major Inflection Point
      Oct 31Seeking AlphaPEPG
      PepGen Inc. (PEPG) Receives a Buy from Stifel Nicolaus

      Detailed price information for Pepgen Inc (PEPG-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailPEPG
      Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and PepGen Inc. (PEPG)

      Detailed price information for Pepgen Inc (PEPG-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailPEPG

      This is the newest page. Registered accounts read further back.